

Welcome address

Dear colleagues,

Welcome to Geneva, welcome to the 20th EORTC-NCI-AACR symposium entitled “Molecular Targets and Cancer Therapeutics”.

This year’s conference will start with the Michel Clavel lecture on the challenges of drug development and a keynote lecture on IGF as a target. There are plenary sessions on “Molecular targets – state of the science” focussing on various molecular targets and tracking their paths for drug development. We will discuss trial methodology through workshops on Phase 0 and Phase II trials and have sessions discussing techniques for target validation. An update of the Response Evaluation Criteria in Solid Tumours (RECIST) will be presented for the first time. We also have a special workshop on drug development in Paediatric oncology.

The scientific committee, 45 members from around the world, succeeded in pulling together a very balanced program. We are very pleased that with their help we have been able to attract leading researchers to come and lecture on their most recent achievements

We are extremely grateful to our partners from the Organizing Committee (A.D. Barker and J. Doroshow from NCI and W. Hait and E. Rubin from AACR) for their commitment and dedication to this meeting. We also wish to express our gratitude to the sponsors of this symposium as well as to the outstanding faculty.

We sincerely hope that it will meet your expectations and we are looking forward to a very successful meeting.

Patrick Schöffski
Scientific Chairman

Martine Piccart
EORTC President